ArticleThe Journal of investigative dermatology2018
HSP70i
Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Engineered antigen-specific regulatory T cells for autoimmune skin conditions.Autoimmunity reviews · 2021Pooled it
- Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation.Clinical reviews in allergy & immunology · 2026Review
- Review
- Oxidative stress in refractory and recurrent vitiligo: from immune amplification mechanisms to potential stratified antioxidant combination therapy.Frontiers in immunology · 2026Review
- Vitiligo.Nature reviews. Disease primers · 2025Review
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Filiform fire needling therapy relieves T cells-mediated melanocyte apoptosis and dysfunction by inhibiting JAK/STAT3 pathway via Mfsd4a in vitiligo.Chinese medicine · 2025Article
- Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model.International journal of molecular sciences · 2025Article
- Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.The Journal of clinical investigation · 2025Review
- The Pathogenesis and Management of Vitiligo.Cureus · 2024Review
- Mechanisms of action ofPharmaceutical biology · 2023Article
- Aetiopathogenesis of Vitiligo.Dermatology practical & conceptual · 2023Review
- The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications.Cells · 2023Review
- Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.International journal of molecular sciences · 2023Review
- Melanocyte-keratinocyte cross-talk in vitiligo.Frontiers in medicine · 2023Review
- Damage-associated molecular patterns in vitiligo: igniter fuse from oxidative stress to melanocyte loss.Redox report : communications in free radical research · 2022Review
- Review
- Current Concepts of Vitiligo Immunopathogenesis.Biomedicines · 2022Review
- Advances in vitiligo: Update on therapeutic targets.Frontiers in immunology · 2022Review
- Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.Clinical reviews in allergy & immunology · 2021Review
Corrections and comments
- Commented on by
- Erratum issuedErratum.2019
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Human HSP70i
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.